About Phialogics

Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.

Press releases

19. April 2023

Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. The startup closes a 600,000 € pre-seed financing round with High-Tech Gründerfonds. The capital will be used to further develop Phialogics’ lead candidate in preclinical models in comparison to the current standard of care and other research approaches. This is a step forward to continue developing Phialogics’ i

Info & Contact

Andreas Ernst, CEO
Pascal Oromi, CBO


Phialogics AG 
c/o Switzerland Innovation Park Basel Area AG
Hegenheimermattweg 167A 
4123 Allschwil 

In portfolio

31. Dec 2022

Dr. Katharina Severin

Investment Manager